Inhibrx Biosciences（INBX）近日获得H.c. Wainwright的正式关注。该机构首次覆盖这家生物科技公司，便果断给出“买入”评级，同时将目标股价设定在245美元。这一举动，无疑为市场注入了一剂强心针。245美元的目标价，相较于当前股价，意味着相当可观的潜在上行空间。此举也反映出华尔街对Inhibrx在研管线及技术平台所蕴含价值的初步认可。H.c. Wainwright此次的积极表态，标志着Inhibrx开始进入更多投资者的视野，其后续的研发进展和商业化潜力将成为市场关注的焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.